CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Refractory Systemic Lupus Erythematosus (GALLOP)

Eligibility Criteria

• * Clinical diagnosis of SLE according to 2019 EULAR/ACR classification criteria for at least 6 months
• * Cohort 1 LN:
• 1. Class III or IV lupus nephritis
• 2. Urine protein-to-creatinine ratio (UPCR) ≥ 0.8 mg/mg
• 3. Refractory to glucocorticoids and at least 2 immunosuppressive therapies
• * Cohort 2 ERL (Patients with class I and II LN may be included in the ERL cohort if their SLEDAI-2K is ≥ 8):
• 1. SLEDAI-2K ≥ 8
• 2. Refractory to glucocorticoids, and at least 2 immunosuppressive therapies
• * Adequate renal, hepatic, pulmonary, and cardiac function, with specific laboratory criteria
• * Females must be either of nonchildbearing potential, defined as postmenopausal or surgically sterile or agree to use a highly effective double barrier method of contraception or vasectomized partner
• * Has active severe central nervous system (CNS) lupus in the previous 3 months from planned LD start date
• * Has received any other investigational treatment for any indication within the 4 weeks or 5 half-lives
• * Prior treatment with cellular therapy (genetically modified cells), gene therapy directed at any target, allogenic or autologous stem cell transplant or organ transplant
• * History of infection with human immunodeficiency virus or evidence of hepatitis B or C virus infection
• * History of hypersensitivity to Cyclophosphamide, Fludarabine, or any of the components of CB-010
• * Received a live vaccine ≤ 6 weeks prior to start of LD
• * Patients for whom magnetic resonance imaging (MRI) studies are contraindicated or who cannot tolerate them